Skip to main content
Clinical Trials/NCT03221907
NCT03221907
Completed
Phase 3

A Multi-center, Randomized, Double-blind, Parallel, Active-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in Peripheral Neuropathic Pain

Daewon Pharmaceutical Co., Ltd.1 site in 1 country352 target enrollmentApril 11, 2016

Overview

Phase
Phase 3
Intervention
GLA5PR GLARS-NF1
Conditions
Pain of Mononeuropathy
Sponsor
Daewon Pharmaceutical Co., Ltd.
Enrollment
352
Locations
1
Primary Endpoint
Daily Pain Rating Scale
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

A multi-center, randomized, double-blind, parallel, active-controlled phase III clinical trial to evaluate the efficacy and safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in peripheral neuropathic pain

Registry
clinicaltrials.gov
Start Date
April 11, 2016
End Date
January 8, 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • both male and female who are over 19-year-old
  • patient whose pain scale is 4\~9
  • patient who has pain of mononeuropathy

Exclusion Criteria

  • patient whose CCr is \<60ml/min
  • patient who has other pain which is not from mononeuropathy
  • patient who is going to have an operation during this study
  • patient who has abnormal ECG

Arms & Interventions

GLA5PR GLARS-NF1 & Pregabalin placebo

GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months

Intervention: GLA5PR GLARS-NF1

GLA5PR GLARS-NF1 & Pregabalin placebo

GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months

Intervention: Pregabalin placebo

GLA5PR GLARS-NF1 placebo & Pregabalin

GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months

Intervention: GLA5PR GLARS-NF1 placebo

GLA5PR GLARS-NF1 placebo & Pregabalin

GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months

Intervention: Pregabalin

Outcomes

Primary Outcomes

Daily Pain Rating Scale

Time Frame: 12-week

Study Sites (1)

Loading locations...

Similar Trials